GLG News by Byetta Prescribers for Diabetes

Unilateral decisions about pharmaceutical detailing makes policy makers feel good, but the bottom line, the patients, are the ones that could pay.

Symlin requires a significant burden on patients without much benefit.  For the lucky few that can get away with basal insulin and Symlin and don’t mind the shots, it may be of some benefit.

The SGLT (Sodium glucose transporter) family of renal glucose transporters is responsible for tubular reabsorption of glucose, preventing what would otherwise be immense loss of glucose in the urine.  An agent inhibiting this transporter, phlorizen, has been used experimentally in understanding...

I have successfully treated 4 patients with fibromyalgia who have not responded to convention recommendations.

Gee whiz, so Cephalon had isolated the enantiomer of provigil that is effetcive. This is the equivalent to AZ isoloating the s enantiomer of ompeprazole to create Nexium and lord ir over prilosec. This is no great feat chemically or pharmacologiclly. What it may mean is millions in profits for investors....

novel medicine, to be considered further good data in terms of glycemic profile improvement further safety data will be needed

Iron is an important aging factor. The greater the body iron stores, the greater the incidence of colon cancer, liver cancer, lung cancer and possibly prostate and breast cancer. Therefore it seems reasonable to believe that also skin cancer may be caused by greater iron, perhaps contained in the...

Avandia and Actos can contribute to heart failure.  This is old news and should be known by all prescribers of these medications. Black Box warnings do not address the underlying cause of inappropriate prescriptions. Education and electronic auditing do.

Pfizer’s Axitinib phase 2 trial suggests a response on metastatic thyroid cancer. However, crucial variables such as pathology, site of metastasis and comparison to a placebo may not have been studied. Therefore, time will tell if this rarely dangerous tumor has a significant treatment.

The future of diabetes care is steering towards novel oral and injectable agents, islet transplants and artificial pancreases. Insulin use in Type 2 diabetic patients may wane, and for Type 1, newer technologies will supplant the need for injections or inhalations.